Control of type III interferon expression and Herpes simplex virus type 1 replication by miR-200

miR-200 对 III 型干扰素表达和 1 型单纯疱疹病毒复制的控制

• 批准号: MR/P011349/1
• 负责人: Jurgen Haas
• 金额: $ 69.05万
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FP011349%2F1
• 关键词: Control; type; III; interferon; expression

Interferons are proteins that are released by cells to combat viruses. There are 3 different types of interferons which differ by the cells that produce them but also the pathogens against which they are active. In our previous work using a new type of genomic screen we showed that the virus that causes cold sores and some other diseases, Herpes simplex virus type 1 (HSV-1), is mainly controlled by a so-called type III interferon (IFN-lambda). Micro RNAs (miRNAs) are small pieces of genetic material within cells that control which proteins are produced. In our recent work we applied another type of genomic screen and identified which miRNAs combat HSV-1. In this project we will combine the outcome of these two genomic screens to investigate how antiviral miRNAs work. From other work which we recently did we know that one of them, miR-200, leads to an increase of IFN-lambda. miR-200 is known to be regulated by an inhibitory protein called ZEB1, but also inhibits ZEB1 itself. This regulatory feedback loop between miR-200 and ZEB1 is known to control a range of different biological processes, both in normal development and cancer. In this project we will investigate if miR-200 inhibits HSV-1 through ZEB1 and IFN-lambda. If this is the case, miRNA creates a functional link between the immune response, normal development and cancer. Our unique approach will help to understand the mechanisms of antiviral miRNAs and could be instrumental for the development of novel drugs against viruses and cancer.

干扰素是细胞释放的用于对抗病毒的蛋白质。干扰素有 3 种不同类型，其不同之处在于产生干扰素的细胞以及干扰素所针对的病原体。在我们之前使用新型基因组筛选的工作中，我们发现引起唇疱疹和其他一些疾病的病毒，即 1 型单纯疱疹病毒 (HSV-1)，主要由所谓的 III 型干扰素 (IFN-lambda) 控制。微小 RNA (miRNA) 是细胞内控制蛋白质产生的小片段遗传物质。在我们最近的工作中，我们应用了另一种类型的基因组筛选并鉴定了哪些 miRNA 可以对抗 HSV-1。在这个项目中，我们将结合这两个基因组筛选的结果来研究抗病毒 miRNA 的工作原理。从我们最近所做的其他工作中，我们知道其中之一 miR-200 会导致 IFN-lambda 的增加。已知 miR-200 受一种名为 ZEB1 的抑制蛋白调节，但也会抑制 ZEB1 本身。已知 miR-200 和 ZEB1 之间的这种调节反馈环可以控制正常发育和癌症中的一系列不同的生物过程。在这个项目中，我们将研究 miR-200 是否通过 ZEB1 和 IFN-lambda 抑制 HSV-1。如果是这样的话，miRNA 就在免疫反应、正常发育和癌症之间建立了功能联系。我们独特的方法将有助于了解抗病毒 miRNA 的机制，并有助于开发抗病毒和癌症的新药物。

项目成果

Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes.

• DOI: 10.1016/j.jhin.2023.02.010
• 发表时间: 2023-05
• 期刊: JOURNAL OF HOSPITAL INFECTION
• 影响因子: 6.9
• 作者: Cotton, S.;McHugh, M. P.;Dewar, R.;Haas, J. G.;Templeton, K.
• 通讯作者: Templeton, K.

Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions.

• DOI: 10.18632/oncotarget.24946
• 发表时间: 2018-04-06
• 期刊: Oncotarget
• 作者: Bhatia R;Kavanagh K;Stewart J;Moncur S;Serrano I;Cong D;Cubie HA;Haas JG;Busby-Earle C;Williams ARW;Howie SEM;Cuschieri K
• 通讯作者: Cuschieri K

The electronic tree of life (eToL): a net of long probes to characterize the microbiome from RNA-seq data.

• DOI: 10.1186/s12866-022-02671-2
• 发表时间: 2022-12-22
• 期刊: BMC MICROBIOLOGY
• 影响因子: 4.2
• 作者: Hu, Xinyue;Haas, Juergen G.;Lathe, Richard
• 通讯作者: Lathe, Richard

Distribution of cellular HSV-1 receptor expression in human brain.

• DOI: 10.1007/s13365-016-0504-x
• 发表时间: 2017-06
• 期刊: Journal of neurovirology
• 影响因子: 3.2
• 作者: Lathe R;Haas JG
• 通讯作者: Haas JG

A Methodology for Remote Microwave Sterilization Applicable to the Coronavirus and Other Pathogens Using Retrodirective Antenna Arrays.

• DOI: 10.1109/jerm.2021.3077110
• 发表时间: 2022-03
• 期刊: IEEE journal of electromagnetics, RF and microwaves in medicine and biology
• 作者: Kossenas K;Podilchak SK;Comite D;Re PDH;Goussetis G;Pavuluri SK;Griffiths SJ;Chadwick RJ;Guo C;Bruns N;Tait-Burkard C;Haas JG;Desmulliez MPY
• 通讯作者: Desmulliez MPY